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ABSTRACT 
 
Accurate DNA replication is crucial for the maintenance of genome integrity. To this 
aim, cells have evolved complex surveillance mechanisms to prevent mitotic entry in 
the presence of partially replicated DNA. ATR and Chk1 are key elements in the signal 
transduction pathways of DNA replication checkpoint; however, other kinases also 
make significant contributions. We show here that the stress kinases p38 and JNK are 
activated when DNA replication is blocked and that their activity allows S/M, but not 
G2/M, checkpoint maintenance when Chk1 is inhibited. Activation of both kinases by 
DNA replication inhibition is not mediated by the caffeine sensitive kinases ATR or 
ATM. Phosphorylation of MKK3/6 and MKK4, p38 and JNK upstream kinases, was 
also observed upon DNA replication inhibition.  Using a genetic approach, we dissected 
the p38 pathway and showed that both p38α and p38β isoforms collaborate to inhibit 
mitotic entry. We further defined MKK3/6 and MK2/3 as the key upstream and 
downstream elements in the p38 signalling cascade after replication arrest. Accordingly, 
we found that the stress signalling pathways collaborate with Chk1 to keep Cyclin 
B1/Cdk1 complexes inactive when DNA replication is inhibited, thereby preventing cell 
cycle progression when DNA replication is stalled. Our results show a complex 
response to replication stress, where multiple pathways are activated and fulfill 
overlapping roles to prevent mitotic entry with unreplicated DNA. 
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INTRODUCTION 
 
Preventing mitotic entry before completion of DNA replication is critical for the 
maintenance of genome integrity.  For this reason cell surveillance mechanisms have 
emerged to block the activation of mitosis-promoting factors when replication forks are 
present. The mechanisms that ensure cell cycle arrest after replication inhibition are part 
of a wider DNA replication checkpoint. This checkpoint monitors the presence of 
stalled or ongoing DNA replication forks and elicits signal transduction pathways that 
lead to the stabilization of arrested forks, the delay of late origin activation, the 
activation of DNA repair, and also the inhibition of mitotic entry.1-3 The checkpoint 
response is essential not only after inhibition of DNA replication caused by the collision 
of the replication fork with damaged DNA, but also when the progression of the fork is 
slowed down because of secondary DNA structures or protein barriers, such as those 
found in natural pausing sites, fragile sites, repetitive sequences, and highly transcribed 
regions.4 Checkpoint failure will cause the collapse of replication forks and premature 
chromosome condensation, thereby increasing chromosomal abnormalities.  
In mammalian cells, the central players in this checkpoint are ATR and its downstream 
effector kinase Chk1. All members of the Cdc25 phosphatase family are phosphorylated 
by Chk1, in a process that leads to the degradation, inactivation or mislocalization of these 
phosphatases. Lack of Cdc25 activity prevents Cdk2 and Cdk1 activation, thus inhibiting 
S-phase progression (intra-S checkpoint response) and mitotic entry (S-M checkpoint 
response).5-8  In addition, ATR and Chk1 promote the activation of DNA repair machinery, 
the stabilization of replication forks and the suppression of late origin activation and 
homologous recombination.1,9-11 However, recent studies show that checkpoint response 
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needs to be locally inactivated in some conditions, since replication resumption relies on 
neighbour origin activation and homologous recombination mechanisms after DNA 
damage or long times of DNA synthesis inhibition.12,13 Coordination of these apparently 
opposite responses is driven by a not well understood mechanism, although ATR- 
dependent activation of Plk1 seems to be essential for the local firing of neighbour origins 
close to stalled forks.14   
The DNA damage checkpoint shares some common events with the DNA replication 
checkpoint. Two major signal transduction pathways triggered by DNA damage have been 
described, the ATM/Chk2 axis, activated after DNA double strand breaks, and the 
ATR/Chk1 axis, which is mainly induced after lesions that are processed into single strand 
stretches of DNA. Both pathways elicit p53 signalling and inactivate Cdc25 phosphatases, 
consequently arresting cell cycle.15 In parallel to the ATR/Chk1 and ATM/Chk2 axes, the 
p38 stress-induced mitogen activated protein kinase (p38 MAPK) has been described as 
the third player in the DNA damage response, contributing to the inhibition of both G1/S 
and G2/M transitions after DNA damage.16-20 A crucial element in the p38-dependent 
DNA damage response is the mitogen-activated protein kinase-activated protein kinase-2 
(MK2). MK2 inhibits Cdc25 phosphatases by phosphorylating them on the same sites as 
those described for Chk1 and Chk217,21and modulates the levels of some proteins critical 
for the maintenance of checkpoint response, such as Gadd45α, by promoting the 
stabilization of their mRNAs.18 Although some studies are contradictory, JNK, another 
stress-activated protein kinase (SAPK), has been reported to regulate the Cdc25 family of 
phosphatases. Consequently, this kinase has been implicated in the control of mitotic entry 
in response to various genotoxic and non-genotoxic stress stimuli.22-25  Interestingly, Chk1, 
MK2 and JNK also control the G2/M transition in a normal cell cycle.26-29  
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Using asynchronously growing fibroblasts, we previously showed that p38 MAPK 
promotes cell cycle arrest when DNA replication is blocked even in cells where Chk1 
was inhibited or depleted.30 Given the relevance of checkpoint functionality in the 
maintenance of genomic stability,3 we aimed to better define the stress-induced MAPK 
signalling cascade responsible for cell cycle arrest upon replication block. Different 
studies showing a role of SAPKs upon various stimuli which induce DNA damage or 
replication checkpoint responses have been published. However, to our knowledge, a 
simultaneous and comprehensive analysis of JNK and p38 pathways in response to 
replication stress in a non-transformed cell line has not been done. 
Our results show that after DNA synthesis inhibition, both p38 α/β and JNK are 
activated and required to achieve a complete ATR/Chk1–independent arrest in a subset 
of cells with unreplicated DNA. Accordingly, we demonstrate that stress signalling 
pathways keep Cyclin B1/Cdk1 complexes inactive in response to DNA replication 
block when Chk1 is inhibited. We have further defined the upstream and downstream 
elements needed for p38 and JNK function after DNA synthesis inhibition. Our findings 
lead to a model where MKK3/6-p38-MK2/MK3 and MKK4/JNK signalling pathways 
act in parallel and independently to ATR/Chk1 to establish and maintain cell cycle 
arrest when DNA replication is blocked. 
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RESULTS 
p38 is specifically activated in arrested S-phase cells and maintains cell cycle arrest 
even when Chk1 is not functional. 
We previously showed that Chk1 and p38 collaborate to inhibit entry into mitosis in the 
presence of HU. To better understand p38 activation under these circumstances, we first 
analyzed now whether its activation was dependent on DNA replication inhibition. To 
this end, NIH3T3 fibroblasts were synchronized and HU was added either in G1 or in S-
phases. Phosphorylation of p38 was observed only when HU was added in S-phase 
cells, indicating that the effect was dependent on the presence of arrested DNA 
replication forks (Fig. 1A and Supplementary Fig. S1A).  Interestingly, p38 was only 
activated at HU concentrations that were completely blocking DNA synthesis, while 
Chk1 phosphorylation was already observed when DNA replication was slowed down 
(Fig. 1B and Supplementary Fig. S1B). Other drugs known to inhibit DNA replication 
as aphidicolin (DNA polymerase α inhibitor), camptothecin (topoisomerase I inhibitor) 
and etoposide (topoisomerase II inhibitor) also induced p38 phosphorylation when 
added in S-phase (Fig 1C).   
We took advantage of etoposide, which induces DNA damage both in S and G2 phases, 
to test whether p38 was specifically acting in S-phase. Etoposide was added to a 
population enriched in S-phase cells, together with Chk1 or p38 inhibitors. As observed 
in figure 1D, late S and G2 damaged cells relied entirely on Chk1 to arrest cell cycle, 
while cells with DNA content clearly below 4n remained arrested after Chk1 inhibition. 
Of note, the observation that a population of cells overrides the cell cycle arrest after 
UCN01 treatment indicates that the drug is in fact inhibiting Chk1 in our model, and as 
extensively proved.31 Single inhibition of p38 after etoposide treatment did not induce 
mitotic entry under our experimental conditions. In contrast, simultaneous inactivation 
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of Chk1 and p38 after DNA damage led to the unscheduled mitotic entry of a new 
subset of cells with DNA content between 2n and 4n, S-phase cells. Similar results were 
obtained using asynchronously growing MEFs (Fig. 1E). These observations indicate 
that the activities of both Chk1 and p38 are essential to prevent mitotic entry of S-phase 
cells with arrested DNA replication. Conversely, p38 activity is dispensable for the cell 
cycle arrest induction in cells with fully replicated DNA. 
 
Both p38 α and β collaborate to inhibit mitotic entry after DNA replication arrest.  
We have previously reported that DNA replication block induces phosphorylation of 
p38 and its downstream kinase MK2 in p38α knockout (KO) MEFs, suggesting that 
another isoform, possibly p38β, is also activated by HU.30 Using p38β KO MEFs, we 
confirmed here that p38α was phosphorylated after HU treatment (Fig. 2A). 
Furthermore, phosphorylation of MK2 after DNA replication inhibition was also 
observed in the p38β KO MEFs, thereby indicating that both isoforms can 
phosphorylate MK2 in response to HU (Fig. 2A). MK2 phosphorylation was abolished 
either after chemical inhibition of p38 α/β (SB203580) or in the double p38α and p38β 
KO MEFs (Fig 2A and Supplementary Fig. S2).  
We next analyzed the ability of these cells to arrest cell cycle after a replication stress.  
We found that the presence of only one of the p38 isoforms (α or β) was sufficient to 
partially maintain cell cycle arrest after HU and UCN01 treatment, while cells deficient 
for both isoforms were not able to prevent mitotic entry after Chk1 inactivation (Fig. 2B 
and Supplementary Fig. S3). Moreover, no further significant mitotic entry was detected 
after p38 chemical inhibition in these conditions, proving that SB203580 dependent 
mitotic entry is due to its effect on p38α and p38β. Of note, under our experimental 
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conditions, UCN01 did not inhibit MK2 activity, measured by HSP27 phosphorylation 
(Supplementary Fig. S2)  
Our findings demonstrate that both p38α and p38β are activated after DNA replication 
block and cooperate in maintaining cell cycle arrest of cells with non-replicated DNA. 
 
p38 activation after DNA replication block is mediated by MKK3 and MKK6 but 
is ATR/ATM-independent.    
Activation of p38 after DNA damage by doxorubicin and camptothecin is ATR/ATM-
dependent, although the mechanism that links ATR/ATM and p38 remains unknown. In 
contrast, p38 activation induced by UV is not mediated by these kinases.17,32,33 As is the 
case with UV, p38 phosphorylation after a replication block is not dependent on 
ATR/ATM, as it was not inhibited by caffeine addition, either when it was added at the 
same time or one hour before the HU treatment (Fig. 3A). To further explore the 
upstream elements needed for p38 activation upon DNA replication block, we analyzed 
the phosphorylation status of MKK3/6, the main MAPK kinases (MAP2K) reported to 
act directly upstream of p38. P-MKK3/6 was observed upon HU treatment (Fig 3B), 
indicating that at least one of them was activated after DNA replication block. We next 
assessed their role in p38 activation in MKK3 and MKK6 single and double KO 
MEFs.34 MKK3/6 double KO MEFs did not activate p38 in response to HU. In contrast, 
phosphorylation of p38 was detected in these cells when they were exposed to a 
different stress agent such as anisomycin, confirming that after some stimuli other 
MAP2K can trigger p38 activation in the absence of MKK3/6 kinases34 (Fig. 3C). This 
suggested that p38 phosphorylation upon DNA replication block is mediated by at least 
one of these kinases. In agreement with these data, MKK3/6 double KO cells were not 
able to inhibit mitotic entry after DNA synthesis arrest and Chk1 inactivation (Fig. 3D 
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and Supplementary Fig. S4). We next examined the contribution of each MAP2K to p38 
phosphorylation upon DNA replication block. As shown in figure 3C, p38 activation 
was detected in both MKK3 and MKK6 single depleted cells upon HU treatment. 
Accordingly, the Chk1-independent induction of cell cycle arrest was partially 
abrogated in the single KO MEFs (Fig. 3D and Supplementary Fig. S4). These 
observations demonstrate that both MKK3 and MKK6 participate in the DNA 
replication checkpoint, working together to activate p38 MAPK and consequently 
reinforcing the cell cycle arrest induced by DNA replication inhibition.  
 
p38 acts through MK2 and MK3 in response to DNA replication block.  
MK2 and MK3 are key p38 effectors in the stress response, with MK2 being the most 
studied so far.35,36  It has been shown that in response to DNA damage MK2 is activated 
by p38, which in turn phosphorylates and inactivates several members of the Cdc25 
family, consequently preventing activation of Cdk1 and mitotic entry.17,21 To test 
whether the p38 function after DNA replication block was dependent on MK2 activity, 
we analyzed the checkpoint response in MK2 KO MEFs. The Chk1-independent 
checkpoint was partially abrogated in MK2 depleted cells, suggesting that MK2 was 
only partially responsible for the p38-dependent cell cycle arrest (Fig. 4 and 
Supplementary Fig. S5). As MK3 is able to phosphorylate the same substrates in vitro 
as MK2, and partial functional redundancy between both kinases has been frequently 
reported,35-37 we wondered whether MK3 was acting together with MK2 after 
replication inhibition. To test the role of this kinase in the DNA replication checkpoint, 
the ability to arrest cell cycle after HU treatment was assayed in MK3 KO cells or 
double MK2 and MK3 KO MEFs. Cells lacking MK3 also had a partial Chk1-
independent response to DNA synthesis arrest. Moreover, when MK2 and MK3 were 
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absent, a higher proportion of cells entered mitosis by the sole inhibition of Chk1. Only 
a minor increase in mitotic entry was observed upon additional p38 inhibition in these 
cells, indicating that the main role of p38 after DNA replication block is driven by its 
downstream kinases MK2 and MK3 (Fig. 4 and Supplementary Fig. S5). We reasoned 
that p38 acts through MK2 and MK3 to prevent mitotic entry in response to DNA 
replication arrest.   
Inhibition of DNA replication leads to Cyclin B1 (CycB1) associated kinase 
inactivation, which correlates with the disappearance of the high-mobility, hypo-
phosphorylated band of the Cdk1 associated to Cyclin B138 (Figs. 5A and 5B). In 
concordance with the low percentage of cells entering mitosis after Chk1 inhibition in 
WT cells (Figs. 2B, 3D and 4), single inactivation of Chk1 did not recover neither the 
appearance of the high-mobility band of Cdk1 nor the kinase activity of the 
CycB1/Cdk1 complexes. Electrophoretic mobility of Cdk1 and complete activity of 
CycB1-associated Cdk1 were only achieved after simultaneous addition of both Chk1 
and p38 inhibitors (Fig. 5A), in correlation with the observed increase of mitotic cells 
(Figs. 2B, 3D and 4). Note that in figure 5A (lower panel), a strong Cdk1 kinase activity 
was detected after simultaneous Chk1 and p38 inactivation, although less CycB1/Cdk1 
complex was immunoprecipitated. Confirming the role of MK2 and MK3 in the S-phase 
checkpoint, the sole inhibition of Chk1 after replication block in MK2/MK3 double 
depleted cells led to the appearance of the lower Cdk1 band, and consequently, to the 
recovery of CycB1/Cdk1 activity (Fig. 5B).  Additional inactivation of p38 in these 
cells did not induce any change neither in Cdk1 electrophoretic mobility nor in its 
kinase activity. An intermediate scenario was found in single MK2 or MK3 KO MEFs, 
thereby indicating that not only MK2 but also MK3 regulates CycB1/Cdk1 activity (Fig. 
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5B). Consequently, we conclude that both, MK2 and MK3, can inhibit CycB1/Cdk1 
activation even in the absence of Chk1 activity.  
 
JNK is activated after DNA replication arrest. 
We wondered whether other stress pathways were also involved in the DNA replication 
inhibition response. JNK kinase has been recently reported to phosphorylate and inhibit 
Cdc25 phosphatases, thereby restraining cell cycle progression and preventing mitotic 
entry under different stress conditions.22-25As shown in figure 6A, HU and aphidicolin 
treatments led to JNK1/2 phosphorylation. Activation of JNK1/2 after HU addition was 
confirmed by the detection of c-jun phosphorylation, one of its main substrates (Fig. 
6B). As in the case of p38, JNK activation was only observed at HU concentrations that 
were completely blocking DNA synthesis (Fig. 6C and Supplementary Fig. S1B). We 
next examined whether DNA replication inhibition was also activating MKK4 and 
MKK7, the direct upstream JNK kinases. HU treatment triggered MKK4 but not MKK7 
phosphorylation (Fig. 6D), suggesting that MKK4 is the MAP2K responsible for JNK 
activation after DNA replication block.  
To further explore the upstream mechanisms involved in MKK4/JNK activation after 
DNA replication arrest, we assessed the role of ATR and ATM in the induction of JNK 
phosphorylation. As in case of p38, caffeine treatment did not prevent phosphorylation 
of JNK (Fig. 6E), indicating that the activation of this SAPK was also independent of 
ATR and ATM activity. 
 
p38 and JNK stress kinases display similar activation kinetics upon DNA synthesis 
inhibition.   
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We sought to analyze the activation profiles of Chk1, p38 and JNK after DNA synthesis 
arrest. To this end, NIH3T3 were synchronized at S-phase and the phosphorylation of 
these kinases was examined at different times upon HU addition. As shown in figure 
6F, the three kinases were rapidly phosphorylated after DNA replication block. Chk1 
maximum activation was achieved one hour after HU treatment. Despite some overlap 
with Chk1 phosphorylation was detected, p38 and JNK kinase activation displayed 
slower activation kinetics, reaching their maximum peak 2 hours after the HU addition. 
Remarkably, both SAPKs had parallel activation profiles. Note that JNK levels 
remained unchanged during the course of the experiment, indicating that the detected 
JNK phosphorylation was not due to an increase in its total levels. These findings show 
that both p38 and JNK kinases are similarly and rapidly activated after DNA replication 
blockade.   
  
JNK contributes to block mitotic entry after DNA replication arrest.  
The similar activation kinetics of p38 and JNK kinases after DNA synthesis block 
prompted us to analyze the role of JNK in the establishment and maintenance of DNA 
replication checkpoint. To this end, we evaluated the ability of JNK1/2 depleted MEFs 
to induce cell cycle arrest upon replication inhibition. Cells lacking JNK1/2 were still 
able to arrest after HU treatment (Fig. 7A and Supplementary Fig. 6). The sole 
inhibition of p38 in these cells did not provoke any increase in mitotic entry 
(Supplementary Fig. 6), indicating that JNK was dispensable in the Chk1-mediated 
arrest. However, after Chk1 inactivation a percentage of JNK1/2 KO cells entered 
mitosis, while, confirming our previous results, WT cells were still arrested. Of note, 
p38 phosphorylation was observed in JNK1/2 KO cells under these conditions (Fig. 
7B). Interestingly, simultaneous inhibition of Chk1 and p38 kinases in JNK1/2 KO cells 
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allowed checkpoint abrogation in a new subset of cells (Fig. 7A and Supplementary Fig. 
6). These observations suggest that JNK1/2 participate in parallel to p38 in the Chk1-
independent checkpoint response to prevent mitotic entry in the presence of 
unreplicated DNA.  
We next examined the contribution of JNK1/2 to CycB1/Cdk1 inhibition after HU 
treatment. In contrast to WT cells, the appearance of the high-mobility Cdk1 band and a 
partial CycB1 associated Cdk1 activation were achieved in HU-treated JNK1/2 DKO 
MEFs when Chk1 was inhibited (Fig. 7C). Higher activity of Cdk1 co-
immunoprecipitated with CycB1 was obtained when p38 was also inactivated, in 
agreement with the increment of mitotic cells observed in the same condition (Figs. 7A 
and 7C). Our data demonstrate that JNK1/2 collaborate with p38 and Chk1 to inhibit 
CycB1/Cdk1 activation after a DNA replication block. 
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DISCUSSION 
Coordination of DNA replication and mitotic entry is essential to ensure genome 
integrity. It is therefore not surprising to find multiple and redundant pathways that 
provide a robust mechanism to inhibit progression into M-phase when DNA replication 
is blocked (S/M checkpoint). We showed here that, when DNA replication is inhibited, 
the stress kinases p38 and JNK are activated in addition to Chk1, triggering parallel 
responses that ensure inhibition of mitotic entry even in the absence of Chk1 activity. 
The p38 MAPK cascade responds to a wide range of stimuli and drives various cellular 
outcomes, that will depend on the cell type, the duration and strength of the signal, the 
crosstalk with other signalling pathways, the different p38 isoforms activated, and the 
downstream effectors modulated by them.39 Using genetically modified MEFs, we 
dissected the essential elements of the p38 MAPK signalling pathway that are involved 
in the DNA replication checkpoint. After DNA replication block, both p38α and p38β 
isoforms are activated and participate in promoting cell cycle arrest. Moreover, our 
results show that p38α/β function is mainly driven by their downstream kinases MK2 
and MK3, as double MK2 and MK3 depleted cells do not show an increase in 
checkpoint abrogation after inhibition of p38 by SB203580. 
Recently, in addition to p38 MAPKs, JNK kinases have also been involved in cell cycle 
arrest induced by either genotoxic or non-genotoxic insults.22-25 In agreement with these 
reports, we showed that JNK1/2 depletion leads to an impaired cell cycle arrest in 
response to replication block when Chk1 is inactivated. 
It has been reported that p38α and MK2 are activated and become crucial in the DNA 
damage checkpoint response of p53-deficient cells.18,32 In that model, both Chk1 and 
p38α/MK2 pathways are essential to maintain the G2 arrest, as the sole inhibition of 
either of them allows unscheduled mitotic entry of cells with unrepaired DNA. Here we 
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proved that not only p38α and MK2 but also JNK, p38β and MK3 are part of the DNA 
replication checkpoint response. Single Chk1, p38 or JNK activities are sufficient for 
the induction and maintenance of the cell cycle arrest after a replication stress in p53-
proficient, non-transformed cells. However, after simultaneous inhibition of Chk1 and 
p38 or JNK kinases some S-phase arrested cells are allowed to escape from cell cycle 
arrest and enter into mitosis with unreplicated DNA. Moreover, we showed that the 
response to DNA damage in S-phase synchronized cells mimics the one induced by a 
replication block, while the DNA damage response of G2 cells strongly relies on Chk1, 
suggesting the existence of different checkpoint mechanisms to arrest cell cycle in each 
cell phase. 
Correlating with their role in the induction of cell cycle arrest, our results show that 
JNK and p38α/β-MK2/MK3, collaborate to maintain CycB1/Cdk1 inactive when DNA 
replication is inhibited in the absence of Chk1 activity. Coordinated dephosphorylation 
of Cdk1 inhibitory sites by Cdc25 phosphatase family and nuclear translocation of the 
complex are essential for the correct mitotic entry.40,41It is well known that Chk1, MK2 
and JNK phosphorylate Cdc25 phosphatases, thereby inducing their cytoplasmic 
localization, degradation or inactivation, depending on the specific phosphorylation site 
or the phosphatase isoform targeted.8,22 We hypothesize that the inactivation of 
CycB1/Cdk1 complex by MK2, MK3 and JNK1/2 kinases after a DNA replication 
block occurs through inhibition of Cdc25 activity, although a different mechanism to 
prevent CycB1/Cdk1 activation cannot be excluded from our data. 
The signalling linking the different DNA lesions to SAPK activation is not well 
understood. Previous reports have shown that p38 activation in response to γ irradiation, 
camptothecin, cisplatin and doxorubicin is ATM or ATR-dependent, while its activation 
in response to UV occurs in the absence of these kinases.20,32 A large family of kinases 
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with MAPK kinase kinase (MAP3K) activity has been described, and some of them 
have been reported to simultaneously activate MKK3/6 and MKK4/7, p38 and JNK 
MAP2Ks respectively.42 A recent work shows, using a FRET (Förster resonance energy 
transfer) biosensor to detect MAP3K activity, that activation of these kinases occurs in 
different cellular compartments depending on the stimulus, MAP3Ks are activated in 
the cytoplasm by anisomycin and in the nucleus after etoposide treatment.43 We 
hypothesize that arrested DNA replication forks may activate a nuclear MAP3K 
upstream of p38 and JNK. One of the MAP3K that has been described as an important 
activator after DNA damage is the TAO2 kinase.33 In that work, the authors 
demonstrate that ATM is needed to induce TAO2 activation, which in turn activates 
MKK3/6 kinases after different DNA damage agents or long exposure to HU. Our data 
indicate that both p38 and JNK activation after replication block are caffeine 
insensitive, suggesting that a different mechanism of those described is driving the 
signal from short term stalled forks to stress activated effectors. 
We further characterized the MAP2Ks involved in p38 and JNK activation in the S-
phase checkpoint. It has been recently shown that MAP2Ks differentially activate each 
p38 isoform depending on the type of stimulus.39  Here we show that after DNA 
replication block both MKK3 and MKK6 are involved in p38α and β activation, since in 
their absence p38 is not phosphorylated after DNA synthesis inhibition and the p38 
replication checkpoint response is not functional. The MAP2Ks reported for JNK 
activation are MKK4 and MKK7.42 We propose here that MKK4 is the specific 
upstream kinase responsible for JNK activation in the DNA replication checkpoint, 
since only MKK4 but not MKK7 phosphorylation is detected after HU treatment. In 
contrast to what was reported for UV,34 after DNA replication block MKK4 cannot 
compensate the MKK3/6 role in p38 activation, as p38 phosphorylation is not detected 
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after HU treatment in double depleted MKK3/6 cells. Our data suggest that, after 
replication block, cells can trigger activation of either MKK3/6-p38-MK2/3 or MKK4-
JNK pathways, which collaborate with Chk1 to restrain cell cycle progression.  
One possibility is that the role of SAPKs upon DNA replication block is completely 
redundant with Chk1, therefore allowing a more robust checkpoint response. However, 
we have found some differences between Chk1 and SAPKs activation. JNK and p38 
activation kinetics differ from Chk1 activation profile after HU treatment. The stress-
kinases phosphorylation is induced later and it is more sustained than Chk1 
phosphorylation. Moreover, p38 and JNK are only activated when DNA replication is 
completely blocked, while Chk1 phosphorylation is already observed when DNA 
replication is slowed down. Therefore, p38 and JNK signalling pathways may control 
additional mechanisms in the replication checkpoint response when cells are exposed to 
more challenging conditions.  
Single cell analysis will help to elucidate whether there are cells that activate one or 
more SAPKs at the same time. In fact, Chk1 inhibition in JNK-depleted cells abrogates 
the HU induced S/M checkpoint response in a subset of cells, while another group of 
cells needs additional inhibition of p38 in order to enter into mitosis with unreplicated 
DNA. These results could indicate that, whereas all cells activate Chk1 after a 
replication block, activation of each one of  the SAPKs is diverse among the cell 
population. Their specific activation in a single cell may depend on the S-phase point 
reached at the moment of DNA replication arrest, the number of stalled replication forks 
or how long a cell has been exhibiting them. Alternatively, SAPKs could be activated 
by all cells with stalled DNA replication forks, but different levels of checkpoint 
kinases activity would be needed to keep CycB1/Cdk1 complexes inactive within the 
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population, making some cells more sensitive to cell cycle arrest abrogation after partial 
checkpoint inhibition. 
Despite Chk1, p38 and JNK activation are readily detected upon DNA replication 
block, we noticed that only a subset of S-phase arrested cells abrogates checkpoint and 
enter mitosis after their simultaneous inactivation. This suggests that additional 
mechanisms, such as transcriptional repression of mitotic inducers30 are playing 
important roles in the checkpoint response. Nevertheless, there is a reproducible, 
significant increase in mitotic entry of cells with unreplicated DNA when Chk1 and 
SAPKs are simultaneously inhibited. These mitotic cells with unreplicated or damaged 
DNA are thought to undergo mitotic catastrophe, a heterogeneous mechanism which 
has been proposed to be an important oncosupressive process, due to its function in 
sensing mitotic failures and eventually eliminating aberrant cells. Defects in the 
execution of this mechanism can ultimately lead to the survival of some damaged, 
aberrant cells harbouring aneuploidies. Components involved in this process, such as 
spindle checkpoint or G1 DNA damage response proteins, are commonly mutated in 
pre-cancerous and cancerous cells.44  Therefore, we propose that, under replication 
stress, partial defects in ATR/Chk1 and SAPK signalling pathways could additionally 
favour genomic instability by increasing the frequence of aberrant mitotic cells.    
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MATERIALS AND METHODS 
 
Cell culture 
Immortalized mouse embryo fibroblasts (MEFs) wild-type (WT), MK2-/-, MK3-/-, 
MK2/3-/-, MKK3-/-, MKK6-/-, MKK3/6-/- and JNK1/2-/- were established from 
embryonic day 13.5 mice with the corresponding genotypes as previously described.34,45-47 
MEFs p38α-/-, p38β-/- and double knockouts p38α-/- and p38β-/- were generated from 
E13.5 mice embryos of the corresponding genotypes by 3T3 spontaneous immortalization 
protocol. MEFs were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% foetal calf serum (FCS). NIH3T3 cells were grown in DMEM 
supplemented with 10% donor bovine serum (DBS), and made quiescent by serum 
starvation. 
 
Drugs  
Drugs and their working concentrations were used as follows:  1.5 mM hydroxyurea (HU), 
50 μM etoposide, 5μg/ml aphidicolin, 10 μg/ml anisomycin, 10μM bromodeoxyuridine 
(BrdU), 1μM camptothecin, 5 mM caffeine and 300 nM for UCN01 (all from Sigma, St 
Louis, MO, USA); 10 μM SB203580 and SB218078 (both from Calbiochem, Merck 
KGaA, Darmstadt, Germany).  
 
Gel electrophoresis, immunoblotting, immunoprecipitation and Cdk1 kinase assay. 
Cell extracts were obtained and run in Laemmli SDS-polyacrylamide gels, and transferred 
to Nitrocellulose membranes as previously described.48 Incubation with antibodies was 
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conducted overnight at 4ºC. Antibodies used:  p38 (sc-728; 1:100), Cdk1 (p34(17)sc-54; 
1:200),  Cyclin B1 (GNS1, sc-245; 1:100), GAP120 (sc-63; 1:100) and Cdk4 (H-303 sc-
749; 1:500) (all from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA); Cyclin B1 
(#4138, 1:1000), P-p38 T180/Y182 (#9211; 1:1000), MAPKAPK2 (#3042; 1:1000), P-
MAPKAPK2 T334 (#3041; 1:1000), JNK (#9252; 1:1000), P-JNK T183/Y185 (#9211; 
1:1000), P-HSP27 S82 (#2401; 1:1000), P-Chk1 S345 (#2341, 1:500), P-MKK3/6 (#9236; 
1:1000), P-SEK1/MKK4(Ser257) (#4514; 1:1000), P-MKK7 (Ser271/Thr275) (#4171; 
1:1000), SEK1/MKK4 (#9152; 1:1000) and MKK7 (#4172; 1:1000) (all from Cell 
Signaling; Beverly, MA, USA); P-c-Jun (BS4045; 1:1000) (Bioworld, St. Louis Park, MN, 
USA). Cyclin B1 was immunoprecipitated with a mouse monoclonal antibody (#05-373, 
from Millipore). Immunoprecipitation and Cdk1 kinase assays were performed as 
described in Rodriguez-Bravo et al.30 
 
Flow cytometry 
Combined analysis of DNA content and phospho-Histone H3 (Ser10) was performed to 
quantify the percentage of mitotic cells. Cells were trypsinized, washed in ice-cold PBS 
and fixed with 70% ethanol overnight at -20ºC. Cells were then permeabilized with PBS 
containing 0.2% Triton X-100 (Sigma, St. Louis, MO, USA) for 10 min at 4ºC, blocked 
with 2% FCS in PBS, and incubated with anti-phospho-H3 for 45 min at room 
temperature (Millipore, #06-570; 1:400). After washing, cells were incubated with 
secondary Alexa488-conjugated antibody (1:500) for 30 min at room temperature, 
washed, and resuspended in PBS containing 20 μg/ml propidium iodide (Sigma, St. 
Louis, MO, USA) dissolved in PBS with 0.2 mg/ml RNAse A (Sigma, St. Louis, MO, 
USA) and 0.1 %(v/v) Triton X-100  prior to analysis by FACS (FACSCalibur). 
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Double analysis of DNA content and BrdU was performed to determine the progression 
through the cell cycle of the S-phase cells. Cells were trypsinized, washed in ice-cold 
PBS and fixed with 70% ethanol overnight at -20ºC. Afterwards, cells were washed and 
treated with 2N HCl dissolved in PBS containing 0.1 %(v/v) Triton X-100 for 15 min at 
room temperature. A Na2B4O7·10H2O buffer with a pH of 8.5 was used twice to 
neutralize the HCl solution. After that, cells were washed and blocked with 3%BSA 
(Sigma, St. Louis, MO, USA) in PBS- containing 0.05%(v/v) Tween (Sigma, St. Louis, 
MO, USA) prior the incubation with anti-BrdU (Abcam, ab6326; 1/250) for 1 hour at 
room temperature. After washing, cells were incubated with secondary Alexa488-
conjugated antibody (1:500) for 45 min at room temperature, washed, and resuspended 
in PBS containing 10 μg/ml propidium iodide dissolved in PBS with 0.1 mg/ml RNAse 
A, prior to analysis by FACS (FACSCalibur). 
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LEGENDS TO FIGURES 
 
Fig. 1. The stress activated protein kinase p38 is activated in response to DNA 
replication block and prevents mitotic entry of cells with unreplicated DNA. A) 
Synchronized NIH3T3 were treated with HU during G1 (0h after activation from 
quiescence) or S-phase (14h after activation from quiescence). p38 and p38 
phosphorylation (P-p38) were analyzed by western blot after a 6h treatment. B) S-phase 
synchronized NIH3T3 cells (14 h after activation from quiescence) were treated with 
indicated HU concentrations during 2h. p38, p38 phosphorylation (P-p38) and Chk1 
S345 phosphorylation (P-Chk1) were analyzed by western blot. GAP120 was used as 
loading control. C) S-phase NIH3T3 synchronized cells (14 h after activation from 
quiescence) were treated with aphidicolin (Aph), camptothecin (CPT) or etoposide 
(Etop) during the indicated time. Cell extracts were analyzed by western blot using 
antibodies to detect phosphorylated p38 (P-p38) and p38. D) S-phase synchronized 
NIH3T3 cells were treated with etoposide (Etop) or with etoposide and UCN01 (UCN) 
or SB203580 (SB) for 3h. DNA content and P-H3 positive cells were analyzed by 
FACS. E) Asynchronously growing MEFs were treated with etoposide (Etop) for 8h 
and during the last 3h UCN01 (UCN01) or SB203580 (SB) were added. DNA content 
and P-H3 positive cells were analyzed by FACS. D) and E) Representative experiments 
are shown.  Total percentages of P-H3 positive cells are shown.  
 
Fig. 2.  Both p38α and β cooperate to inhibit mitotic entry in DNA replication 
checkpoint.  
Asynchronously growing MEFs were non-treated (C) or treated with HU for 10h and 
during the last 5h UCN01 (UCN) or SB203580 (SB) were added. A) Cell extracts were 
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analyzed by western blot to detect phospho-p38 (P-p38), phospho-MK2 (P-MK2), MK2 
and GAP120 (loading control). B) Graphs show the percentage of P-H3 positive cells 
after each treatment analyzed by FACS. Mean±SEM of at least 3 independent 
experiments are shown. WT: wild type; p38α KO: p38α knockout; p38β KO: p38β 
knockout; p38α/β DKO: p38α and β double knockout. 
 
Fig. 3. Both MKK3 and MKK6 collaborate to activate the p38-dependent 
checkpoint response to HU treatment.  A) Asynchronously growing MEFs were left 
untreated (C), or treated with HU for 5h (HU), caffeine alone for 6h (Caff Pre), or HU 
and caffeine together for 5h (HU + Caff). Caffeine was also added 1h before the HU 
treatment (HU + Caff Pre). Cell extracts were analyzed by western blot using antibodies 
to detect phospho-p38 (P-p38), phospho-Chk1 S345 (P-Chk1) or GAP120 (used as a 
loading control). B) Asynchronously growing MEFs were treated with HU for the 
indicated time, 1h with anisomycin (An) or left untreated (C). Cell extracts were 
analyzed by western blot to detect phospho-MKK3/6 (P-MKK3/6), MKK6 and GAP120 
(loading control). C) Asynchronously growing MEFs were left untreated (C), or were 
treated with anisomycin for 1h (An), or with HU for the indicated times. Cell extracts 
were analyzed by western blot to detect phospho-p38 (P-p38) or p38. D) 
Asynchronously growing MEFs were non treated (C) or treated with HU for 10h. 
UCN01 (UCN) or SB203580 (SB) were added when indicated during the last 5h of the 
HU treatment. Graphs show the percentage of P-H3 positive cells after each treatment 
analyzed by FACS. Mean±SEM of at least 3 independent experiments are shown.  WT: 
wild type; MKK3 KO: MKK3 knockout; MKK6 KO: MKK6 knockout; MKK3/6 DKO: 
MKK3/6 double knockout. 
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Fig. 4. Both MK2 and MK3 are key p38-downstream elements in the DNA 
replication checkpoint. Asynchronously growing MEFs were non treated (C) or treated 
with HU for 10h and during the last 5h SB218078 (2180) or SB203580 (SB) were 
added. Graphs show the percentage of P-H3 positive cells after each treatment analyzed 
by FACS. Mean±SEM of at least 3 independent experiments are shown.  WT: wild 
type; MK2 KO: MK2 knockout; MK3 KO: MK3 knockout; MK2/3 DKO: MK2/3 
double knockout. 
 
Fig. 5. Inhibition of CycB1 associated kinase activity after replication block is 
Chk1, p38 and MK2/3-dependent.  A) Asynchronously growing MEFs were treated 
with HU for 10h and during the last 5h SB218078 or SB203580 were added. Cells were 
lysed and Cyclin B1 immunoprecipitated. Upper panel: Immunoprecipitated Cyclin B1 
and associated Cdk1 were analyzed by western blot. Lower panel: after Cyclin B1 
immunoprecipitation, Cdk1 activity in each condition was evaluated by performing an 
H1-kinase assay. In parallel, Cdk1 levels of the same immunoprecipitates were 
analyzed. (B) MK2 knockout, MK3 knockout and MK2/MK3 double knockout MEFs 
were treated as in (A). Immunoprecipitated CycB1 and Cdk1-associated to CycB1 were 
detected by western blot (left panels). In parallel, CycB1-associated Cdk1 activity was 
assayed (right panels). MK2 KO: MK2 knockout; MK3 KO: MK3 knockout; MK2/3 
DKO: MK2/3 double knockout.  
 
Fig 6. JNK stress kinase is activated after DNA replication block.  
A)  Asynchronously growing MEFs were treated with HU or Aphidicolin (Aph) for 10h 
or with anisomycin (An) for 1h. Cells were harvested and JNK phosphorylation (P-
JNK) was analyzed by western blot. B) Asynchronously growing MEFs were treated 
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with anisomycin (An) for 1h or with HU for 10h and during the last 5h UCN01 (UCN) 
or SB203580 (SB) were added. Cell extracts were analyzed by western blot using 
antibodies to detect phosphorylated c-jun (P-c-jun). C) S-phase synchronized NIH3T3 
cells (14 h after activation from quiescence) were treated with indicated HU 
concentrations during 2h. Cell extracts were analyzed by western blot using antibodies 
to detect phosphorylated JNK (P-JNK). D) Asynchronously growing MEFs were treated 
with HU for the indicated time or 1h with anisomycin (An). Cell extracts were analyzed 
by western blot to detect phospho-MKK4 (P-MKK4), phospho-MKK7 (P-MKK7), total 
MKK4 and total MKK7. E) Asynchronously growing MEFs were treated with HU for 
5h, with caffeine for 6h, or with HU plus Caffeine (1h of caffeine pre-incubation prior 
to HU addition and 5h together with HU). Cell extracts were analyzed by western blot 
to detect P-JNK. F) S-phase synchronized NIH3T3 were treated with HU for the 
indicated times. Chk1, p38 and JNK phosphorylation, and total JNK1/2 were 
determined by western blot using the specific antibodies (P-Chk1, P-p38, P-JNK1/2, 
and JNK1/2). C: control, non–treated cells. GAP120 was used as loading control. 
 
Fig. 7. JNK collaborates to inhibit entry into mitosis and CycB1-associated kinase 
activity after HU treatment. 
A) Asynchronously growing wild type (WT) and JNK1/2 double knockout (JNK1/2 
DKO) MEFs were treated with HU for 10h and during the last 5h UCN01 (UCN) or 
SB203580 (SB) were added. Graph shows the percentage of P-H3 positive cells (mean 
± SEM) after each treatment analyzed by FACS. B) Asynchronously growing JNK1/2 
double knockout (JNK KO) MEFs were treated with anisomycin for 1h (An) or with 
HU for 10h and during the last 5h UCN01 (UCN) or SB203580 (SB) were added. Cell 
extracts were analyzed by western blot to detect phospho-JNK (P-JNK), phospho-p38 
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(P-p38), JNK and p38. C) Asynchronously growing wild type (WT) or JNK1/2 double 
knockout (JNK1/2 DKO) MEFs were treated with HU for 10h, during the last 5h 
UCN01 (UCN01) or SB203580 (SB) were added. Cells were lysed and Cyclin B1 
immunoprecipitated. Immunoprecipitated CycB1 and associated Cdk1 were analyzed by 
western blot (left panels). In parallel, an H1-kinase assay was performed in CycB1 
immunoprecipitated extracts (right panels). 
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